10-Q: Assure Holdings Corp. Reports Q2 2024 Results, Navigates Strategic Shifts and Financial Challenges

Sentiment:

Quarterly Report 27 September 2024 4:55 PM

Assure Holdings Corp. reports a net loss of $4.016 million for the six months ended June 30, 2024, amid strategic shifts including the sale of clinical assets and termination of a merger agreement.

Delay expectedThe company failed on a timely basis to satisfy the required conditions including the raising of the needed equity, the assignment of assets, the issuance of shares and as a consequence the settlement arrangements have not and cannot be completed as agreed in the Memorandum of Understanding.

Capital raiseThe Company intends to seek equity or debt financing and have implemented significant cost cutting measures to mitigate its going concern.Such financings may include the issuance of shares of common stock, warrants to purchase common stock, convertible debt or other instruments that may dilute current stockholders.Financing may not be available on acceptable terms depending on market conditions at the time the Company seeks financing.

Worse than expectedRevenue decreased significantly to $10 thousand for the six months ended June 30, 2024, compared to $182 thousand in the prior year.The company's cash position as of June 30, 2024, was $45 thousand, and working capital was negative $19.1 million.

Summary

Assure Holdings Corp. reported financial results for the quarter ended June 30, 2024.
The company has undergone significant strategic changes, including the sale of its clinical operations and the termination of a merger agreement with Danam.
For the six months ended June 30, 2024, Assure reported a net loss of $4.016 million, compared to a net loss of $9.196 million for the same period in 2023.
Revenue decreased to $10 thousand for the six months ended June 30, 2024, from $182 thousand for the same period in 2023.
The company's cash position as of June 30, 2024, was $45 thousand, and working capital was negative $19.1 million.
Assure's ability to continue as a going concern is in substantial doubt, and the company is seeking equity or debt financing.
The company has been delisted from the Nasdaq and is now trading on the OTC Markets.
Assure is pursuing strategic opportunities, including potential acquisitions and new lines of business.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with some improvements in net loss but significant concerns about revenue, cash position, and the company's ability to continue as a going concern. The delisting from Nasdaq and the need for additional financing add to the negative sentiment.

Positives

Net loss decreased from $9.196 million to $4.016 million for the six months ended June 30, 2024, compared to the same period in 2023.
The sale of clinical assets resulted in a gain of $666 thousand for the three months ended March 31, 2024.
The company is actively pursuing strategic alternatives, including potential acquisitions and new lines of business.
The company has entered into a binding memorandum of understanding with Centurion to settle its debt obligations through asset assignments and share issuance.

Negatives

Revenue decreased significantly to $10 thousand for the six months ended June 30, 2024, compared to $182 thousand in the prior year.
The company's cash position as of June 30, 2024, was $45 thousand, and working capital was negative $19.1 million.
Assure's ability to continue as a going concern is in substantial doubt.
The company is in default on a $1 million convertible note issued to Danam.
Assure has been delisted from the Nasdaq and is now trading on the OTC Markets.
The company terminated its merger agreement with Danam on June 11, 2024, and is seeking reimbursement for fees and expenses.

Risks

The company's ability to continue as a going concern is in substantial doubt.
Assure is dependent on securing equity or debt financing, which may not be available on acceptable terms.
The company is in default on a $1 million convertible note issued to Danam.
The delisting from Nasdaq could lead to reduced liquidity, limited market quotations, and decreased ability to raise capital.
The company faces risks associated with the transition to the OTC Markets.
The company is subject to risks related to the settlement of debt obligations with Centurion.
The company is subject to risks related to the settlement of other claims and obligations.

Future Outlook

The Company plans for the business to continue to operate in Montana and Arizona while management continues to assess other strategic opportunities in the near term, which may include the acquisition of additional operational assets, acquiring new lines of business or engaging in other strategic transactions.

Industry Context

The IONM industry is characterized by the need for specialized technical and professional services during invasive surgical procedures. Assure's strategic shift reflects a move away from a broader service model to focus on limited markets and explore new strategic opportunities. The company's challenges in maintaining Nasdaq listing and securing financing highlight the competitive pressures and financial constraints within the industry.

Comparison to Industry Standards

It is difficult to compare Assure's results directly to industry standards due to its unique strategic shifts and financial challenges.
However, some comparable companies in the neuromonitoring services industry include NuVasive and Medtronic, which have a broader range of products and services and stronger financial positions.
Assure's revenue decline and net losses are significantly different from the financial performance of larger, more established companies in the industry.
The company's focus on limited markets and exploration of new strategic opportunities may be a strategy to differentiate itself and improve its financial performance in the long term.

Stakeholder Impact

Shareholders face significant risks due to the company's financial challenges, delisting from Nasdaq, and potential dilution from future equity offerings.
Employees may be affected by cost-cutting measures and strategic shifts.
Customers may experience changes in service availability as the company focuses on limited markets.
Creditors face increased risk due to the company's financial instability and potential default on debt obligations.

Next Steps

The Company will continue to operate in Montana and Arizona.
Management will continue to assess other strategic opportunities in the near term, which may include the acquisition of additional operational assets, acquiring new lines of business or engaging in other strategic transactions.
The Company intends to submit an application to the OTCQB for quotation of its common stock.
The Company has 15 days after the date it received notice of the Panels decision (which is July 22, 2024) to request in writing that the Nasdaq Listing and Hearing Review Council (the Council) review the decision.

Key Dates

Date	Description
September 24, 2007	Montreux Capital Corp was formed in British Columbia, Canada.
May 15, 2017	Assure Holdings Corp. became a Nevada corporation.
August 25, 2015	Assure Neuromonitoring, LLC was formed.
November 2, 2016	Assure Networks, LLC was formed.
November 7, 2016	Assure Holdings, Inc. was formed.
April 20, 2020	Assure Equipment Leasing, LLC was formed.
June 9, 2021	Assure issued a debenture to Centurion Financial Trust.
September 2023	The Board of Directors initiated a process to explore strategic alternatives.
March 11, 2024	The Company entered into an asset purchase agreement with National Neuromonitoring Services, LLC.
March 26, 2024	Assure closed the sale transaction of clinical assets.
February 12, 2024	Assure entered into a merger agreement with Danam.
April 8, 2024	The Company entered into a partial waiver and amendment agreement with Danam and issued a convertible note to Danam.
May 15, 2024	Original outside date for Merger consummation.
June 11, 2024	Assure terminated the Merger Agreement with Danam.
June 30, 2024	End of the reporting period for the quarterly report.
July 8, 2024	The Company effectuated an eighteen-to-one reverse stock split.
July 22, 2024	The Nasdaq notified Assure that the Panel determined to delist the Company's common stock.
July 24, 2024	Trading of the Company's securities was suspended on Nasdaq and began on the OTC Markets.
August 30, 2024	The Company entered into a binding amended and restated memorandum of understanding with Centurion.
October 10, 2024	Deadline for completing the terms of settlement with Centurion.

Keywords

Assure Holdings, IONM, Financial Results, Strategic Alternatives, Clinical Operations, Merger Agreement, Convertible Debt, Nasdaq Delisting, OTC Markets, Centurion, Debt Settlement, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.